Compare Globus Medical Inc. Class A Common Stock (GMED) vs Sprott Uranium Miners ETF (URNM) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Globus Medical Inc. Class A Common Stock vs Sprott Uranium Miners ETF — how do they compare? Globus Medical Inc. Class A Common Stock trades at $76.58 (market cap $10.25B), while Sprott Uranium Miners ETF trades at $42 (market cap $1.78B). The key difference: Globus Medical Inc. Class A Common Stock is far larger — about 5.8× Sprott Uranium Miners ETF's market cap, and Globus Medical Inc. Class A Common Stock is trading nearer its 52-week high, Sprott Uranium Miners ETF nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Globus Medical Inc. Class A Common Stock for 0 Days and Sprott Uranium Miners ETF for 62 Days on average.
| GMED | URNM | |
|---|---|---|
Market Cap | $10.25B | $1.78B |
Volume | 1,108,124 | 1,008,269 |
Sector | Health | Commodities - Metals/Agriculture |
52-Week High | $96.82 | $83.99 |
52-Week Low | $58.33 | $42.42 |
Typical Hold Time | 0 Days | 62 Days |
Enterprise Value | $9.76B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Globus Medical (GMED) trades at $76.32, showing minimal daily movement with a 0.1% gain. The stock demonstrates strong fundamental performance with consistent earnings beats in recent quarters and robust profitability metrics including 68.55% gross margins and 17.03% net income margins. Technical indicators suggest neutral positioning near key support at $73 with resistance at $74. Recent developments include new product showcases at industry conferences and upcoming Q3 earnings release.
GMED presents a compelling investment case with strong analyst support (72% buy rating) and 25% upside to consensus target of $95.13. The company maintains solid revenue growth trajectory and debt-free balance sheet, though investors should monitor competitive pressures in medical devices and potential margin compression as revenue scales. Near-term catalysts include Q3 earnings results expected November 5, 2026.
URNM trades at $44.51, down 1.44% on the day, with a bearish technical signal from moving averages and oscillators. Recent news highlights uranium's role in AI energy demand and nuclear expansion, but financial ratios are unavailable. The ETF tracks uranium miners, with support at $43 and resistance at $46.
Long-term prospects are supported by nuclear energy growth and AI power needs, but short-term price volatility and lack of fundamental data pose risks. Investor sentiment is mixed, with bullish articles on uranium's future but technical indicators suggesting caution.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Globus Medical Inc. Class A Common Stock
Globus Medical, Inc. develops and manufactures medical devices for treating musculoskeletal disorders, including spine, orthopedic trauma, and neurosurgical products. It operates in US and internationally, serving surgeons and healthcare providers.
Read more on GMED →About Sprott Uranium Miners ETF
URNM is a pure-play ETF that invests in the global uranium industry. It provides exposure to companies involved in the mining, exploration, and production of uranium, as well as physical uranium holdings, with top assets like Cameco, Uranium Energy Corp, and the Sprott Physical Uranium Trust.
Read more on URNM →
